6:06 AM ET
8-K
Stock Plan Amendment
Passage BIO Stock Plan Amendment
Passage Bio stockholders approved the 2026 Equity Incentive Plan at a special meeting, which will become effective upon the completion of the company's merger with Remix Therapeutics. The plan reserves 5,772,500 shares for issuance and is intended to replace existing equity incentive plans from both companies. The plan also includes an evergreen provision for annual share increases through 2036.
- Counterparty
- Remix Therapeutics, Inc.